Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncaspar

(Pegaspargase)

ApprovedProtein / enzyme

Pegaspargase is used to treat certain types of blood cancer, particularly acute lymphoblastic leukemia (ALL), by helping to kill cancer cells. It works by depleting an amino acid that leukemia cells need to survive.[2] Oncaspar is currently approved and in use across 15 indications[4].[1]

Oncaspar is one of 178 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Approved.

15

Indications

100

Total Trials

32

Active Trials

177

Competitors

11

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Acute Lymphoblastic LeukemiaActive, not recruiting

Lymphoid LeukemiaUnknown

T Acute Lymphoblastic LeukemiaCompleted

Acute Lymphoblastic Leukemia, PediatricActive, not recruiting

Recurrent B Acute Lymphoblastic LeukemiaActive, not recruiting

Adult T Acute Lymphoblastic LeukemiaActive, not recruiting

T Lymphoblastic Leukemia/lymphomaNot yet recruiting

Natural Killer/t-Cell LymphomaNot yet recruiting

Down SyndromeRecruiting

LymphomaUnknown status

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Lymphoid LeukemiaPreclinical

Unknown

T Acute Lymphoblastic LeukemiaPhase 3

Completed

Acute Lymphoblastic Leukemia, PediatricPhase 3

Active, not recruiting

Recurrent B Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Adult T Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

T Lymphoblastic Leukemia/lymphomaPreclinical

Not yet recruiting

Natural Killer/t-Cell LymphomaPhase 2

Not yet recruiting

Down SyndromePhase 2

Recruiting

LymphomaPhase 3

Unknown status

Showing 10 of 15 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncaspar

Zofran

Cabenuva

Norvir

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Kenalog

BBausch Health Americas, Inc.

Nuvigil

NNuvo Research GmbH

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

Bristol-Myers Squibb

Decadron

QQuince Therapeutics S.p.A.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT02883049

Phase 2Recruiting

T Acute Lymphoblastic Leukemia

NCT00501826

Post-ApprovalRecruiting

Children

NCT03844360

Phase 1/2Active, not recruiting

T-Cell Acute Lymphoblastic Leukemia

NCT03808610

Phase 2Active, not recruiting

Recurrent B Acute Lymphoblastic Leukemia

NCT02981628

Q1 2027

Phase 1/2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT05192889

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia48 trials

Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01403415·13 enrolled

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00967057·470 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Show 45 more trials

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002816·120 enrolled

Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL

Completed·CChildren's Oncology Group·N/A·NCT01225874·3,762 enrolled

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00557193·218 enrolled

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00049569·126 enrolled

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00075725·3,154 enrolled

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00016302·100 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Completed·CChildren's Oncology Group·N/A·NCT00096135·168 enrolled

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown status·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00343369·550 enrolled

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Unknown status·SSun Yat-sen University·Phase 2·NCT02660762·100 enrolled

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00882206·15 enrolled

Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia

Unknown status·SSun Yat-sen University·Phase 2·NCT03318419·50 enrolled

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00558519·318 enrolled

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00103285·5,377 enrolled

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00002785

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01190930·9,350 enrolled

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00671034·166 enrolled

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02883049·5,949 enrolled

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00022126·6 enrolled

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT01005914·11 enrolled

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00022737·220 enrolled

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Completed· Incyte logo

Incyte·Phase 2·NCT02723994·171 enrolled

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02828358·78 enrolled

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005596·1,076 enrolled

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005945·3,054 enrolled

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Completed·CChildren's Oncology Group·Phase 1/2·NCT00098839·134 enrolled

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002744·1,970 enrolled

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05192889·35 enrolled

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Completed·CChildren's Oncology Group·Phase 1·NCT00866307·104 enrolled

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005585·838 enrolled

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05660473·100 enrolled

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00890656·90 enrolled

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Completed·CChildren's Oncology Group·Phase 1·NCT03792256·12 enrolled

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT00720109·63 enrolled

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting·MMartin Schrappe·Phase 3·NCT03643276·5,000 enrolled

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

Recruiting·—·Phase 1·NCT05157971·24 enrolled

Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Unknown status·MMedical Research Council·Phase 3·NCT00003437·1,800 enrolled

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03007147·352 enrolled

Treatment of Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults (AYAs)

Recruiting·DDana-Farber Cancer Institute·Phase 2·NCT07227584·67 enrolled

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02003222·488 enrolled

Randomized Study of Intravenous Calaspargase Pegol (SC-PEG Asparaginase) and Intravenous Oncaspar in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT01574274·240 enrolled

Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)

Recruiting·UUniversity of Chicago·Phase 1·NCT03571321·15 enrolled

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Active, not recruiting·SSt. Jude Children's Research Hospital·Preclinical·NCT02553460·50 enrolled

Lymphoma16 trials

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

Unknown status·SSun Yat-sen University·Phase 2·NCT02705508·35 enrolled

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

Completed·RRuijin Hospital·Phase 2·NCT02825147·40 enrolled

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Recruiting·—·Phase 1/2·NCT06376721·43 enrolled

Show 13 more trials

GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

Unknown status·SSun Yat-sen University·Phase 2·NCT01991158·30 enrolled

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 3·NCT02631239·256 enrolled

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04917250·15 enrolled

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Recruiting·SSun Yat-sen University·Phase 3·NCT04365036·207 enrolled

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 2·NCT04096690·22 enrolled

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

Terminated·SSun Yat-sen University·Phase 2·NCT02533323·50 enrolled

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Unknown status·HHuiqiang Huang·Phase 3·NCT02085655·264 enrolled

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Unknown status·HHunan Cancer Hospital·Phase 2·NCT02918747·100 enrolled

Combination Chemotherapy in Treating Children With Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002590·221 enrolled

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Terminated·SSun Yat-sen University·Phase 3·NCT02359162·50 enrolled

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Not yet recruiting·CCStone Pharmaceuticals·Phase 3·NCT05700448·150 enrolled

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Unknown status·SSun Yat-sen University·Phase 2·NCT01921790·30 enrolled

Tislelizumab Plus Dose-Dense P-GemOx and Radiation Therapy for Early-Stage Intermediate/High-Risk Extranodal NK/T-Cell Lymphoma: A Multicenter Phase II Trial

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT05254899·54 enrolled

B Acute Lymphoblastic Leukemia4 trials

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06124157·222 enrolled

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Recruiting·CChildren's Oncology Group·Phase 3·NCT03959085·5,951 enrolled

A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT05602194·440 enrolled

Show 1 more trial

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03914625·6,720 enrolled

Children2 trials

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Recruiting·WWei Zhao·Phase 4·NCT03844360·1,500 enrolled

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT01228331·745 enrolled

Leukemia2 trials

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002812·2,078 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002766·170 enrolled

22 more indications

Treatment2 trials

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Unknown status·—·Phase 2·NCT04337593·20 enrolled

L-DEP as an Initial Treatment for EBV-HLH

Unknown status·—·Phase 3·NCT02912702·120 enrolled

Chidamide2 trials

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564704·80 enrolled

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03553238·70 enrolled

Acute Leukemia2 trials

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05521087

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Unknown status·DDutch Childhood Oncology Group·N/A·NCT00550992·445 enrolled

T-cell acute lymphoblastic leukemia2 trials

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03808610·50 enrolled

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06210750

Recurrent B Acute Lymphoblastic Leukemia2 trials

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT02981628·80 enrolled

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02101853·669 enrolled

T Acute Lymphoblastic Leukemia2 trials

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00501826·160 enrolled

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00408005·1,895 enrolled

Histiocytosis1 trial

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Unknown status·—·Phase 3·NCT02631109·120 enrolled

Blinatumomab1 trial

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06554626·20 enrolled

Relapsed or Refractory1 trial

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Terminated·—·Phase 2·NCT02535806·2 enrolled

Relapsed/Refractory1 trial

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Unknown status·—·Phase 2·NCT04405375·29 enrolled

Relapsed/Refractory B-cell ALL1 trial

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Active, not recruiting·UUniversity of Virginia·Phase 1·NCT03962465·36 enrolled

Adult1 trial

A Study of PD5K3 in Healthy Adult Volunteers

Completed·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 1·NCT06527781·28 enrolled

Anti-PD-1 Antibody1 trial

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Unknown status·SSun Yat-sen University·Phase 2·NCT04676789·30 enrolled

Chemotherapy1 trial

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT01483690·23 enrolled

B-cell acute lymphoblastic leukemia1 trial

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00381680·275 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Down syndrome1 trial

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04546399·461 enrolled

Natural Killer/T-cell Lymphoma1 trial

A Prospective Multicenter Response-Adapted Treatment Study Based on Early Response Assessment After GELAD Induction Chemotherapy in Early-Stage Extranodal NK/T-Cell Lymphoma

Not yet recruiting·FFudan University·Phase 2·NCT07768943·620 enrolled

Drug/Agent Toxicity by Tissue/Organ1 trial

Treatment of Acute Lymphoblastic Leukemia in Children

Completed·DDana-Farber Cancer Institute·Phase 3·NCT00400946·800 enrolled

T lymphoblastic leukemia/lymphoma1 trial

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Not yet recruiting·CChildren's Oncology Group·Preclinical·NCT07072585·1,708 enrolled

Adult T Acute Lymphoblastic Leukemia1 trial

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02112916·847 enrolled

Acute Lymphoblastic Leukemia, Pediatric1 trial

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active, not recruiting·DDana-Farber Cancer Institute·Phase 3·NCT03020030·560 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 1, 1994

ONCASPAR

NDA BLA103411

Feb 1, 1994

ONCASPAR

BLA BLA103411

Jul 24, 2006

ONCASPAR

NDA BLA103411

Mar 23, 2011

ONCASPAR

NDA BLA103411

Apr 22, 2014

ONCASPAR

NDA BLA103411

Oct 7, 2016

ONCASPAR

NDA BLA103411

Jan 3, 2019

ONCASPAR

NDA BLA103411

Jun 17, 2020

ONCASPAR

NDA BLA103411

Nov 2, 2021

ONCASPAR

NDA BLA103411

Dec 22, 2022

ONCASPAR

NDA BLA103411

Mar 13, 2024

ONCASPAR

NDA BLA103411

Sources

References

[1]
ClinicalTrials.gov — 100 trial records for Pegaspargase. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Oncaspar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pegaspargase compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pegaspargase. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA103411). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Servier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: SServier

Related News